Stanford University
Palo Alto, California, 94304, United States
NCT Number: NCT05838482
The purpose of the study is to collect data to evaluate utility of the using photon-counting CT in a clinical setting.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Palo Alto, California, 94304, United States
Data collected in this study includes an assessment of image quality parameters including spatial resolution, image contrast, and noise that will evaluate the product and how this photon-counting CT technology can be used to reduce the overall radiation dose in CT imaging, and enhance clinical applications for CT technology. This data and analysis will help support regulatory submission.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Enrolled subjects will complete an exam using the photon-counting CT, with or without IV contract as indicated. Images will then be compared with the previously acquired CT conducted as standard of care.
Time frame: 1 year
Number of Participants with raw investigational photon-counting CT scan data along with prior standard of care diagnostic CT exam data/images
Time frame: 1 year
Reconstructed images produced from the raw investigational photon-counting CT scan will be scored for image quality using a Likert Scale (1 - Non-Diagnostic to 5 - Excellent Image Quality)
GE Healthcare
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04781296
CT Photon-Counting
Stockholm, Sweden
View Trial Details